Novo Nordisk to invest $2.3 billion in French facility to address GLP-1 drug shortage
.png)
Manufacturing for the diabetes and weight-loss drugs Ozempic and Wegovy is expected to increase with a billion-dollar investment Novo Nordisk production site located in Chartres, France.
Danish pharmaceutical giant Novo Nordisk announces a $2.3 billion investment into its Chartres, France manufacturing site to boost production of weight-loss and diabetes drugs such as Wegovy and Ozempic, among others.
A growing supply crisis of semaglutide drug products has European healthcare systems worried. The off-label use of Ozempic as an obesity treatment. Ozempic in particular has faced supply shortages in Europe because of its popularity in weight-loss treatment, while Wegovy is not yet widely available in Europe. Some nations are considering bans on off-label prescriptions for Ozempic; Germany has considered banning exports of the drug, while Belgium banned non-diabetes related prescriptions of Ozempic. Novo Nordisk itself has introduced rations for Ozempic starter kits in response to increased demand for weight-loss treatments. Earlier in November 2023, Novo Nordisk announced an increase in investment to $6 billion for production within Denmark.
Estimate analysis of the obesity drug market shows a potential worth of $100 billion by 2030. The investment into the French manufacturing plant will also serve as a boost for France’s economy as it faces a global economic slowdown. During the ‘Choose France’ summit earlier in the year, the office of French President Emmanuel Macron announced they had convinced Novo Nordisk CEO Lars Fruergaard Jorgensen to invest in the French manufacturing site. However, Novo Nordisk has yet to comment on this.
The investment will significantly increase the several types of manufacturing required for the production of GLP-1 drug class, with specialist operations for the filling of injection pens with the API semaglutide. Assembly and packaging operations of the injection pens will also be increased.
Source: Novo Nordisk invests $2.3 billion in France to boost obesity drug production [Accessed November 29, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-invests-23-mln-france-boost-output-2023-11-23/
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...